FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPROVAL										
	OMB Number:	3235-0287									
l	Estimated average burden										
l	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Sheridan John F						2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC TNDM										able)	g Perso	10% Ow Other (s	ner
(Last) (First) (Middle) 12400 HIGH BLUFF DRIVE					3. Date of Earliest Transaction (Month/Day/Year) 05/15/2024									PRESIDENT & CEO					
(Street) SAN DIEGO CA 92130					- 4. I -	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check ne) X Form filed by One Reporting Po Form filed by More than One R Person				1
(City) (State) (Zip)					R	Rule 10b5-1(c) Transaction Indication													
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - No	n-Deri	vativ	e Se	curit	ies Ac	quired,	Dis	posed o	f, or Be	enefic	ially	/ Owned				
Date				Date	Transaction ate lonth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Transaction Code (Instr.						es Formially (D) (I) (I)		Direct Indirect Istr. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) c	r Pri	ce	Reported Transact (Instr. 3 a	tion(s)			(Instr. 4)
Common	Stock			05/1	05/15/2024				A		978(1)) A	\$1	\$15.64 3),866		D	
Common	05/1	15/2024				M		792	A		\$ <mark>0</mark>	31,	,658		D				
Common Stock 05/1						5/2024					402	D	\$4	7.37	31,	,256		D	
Common Stock 05/15						5/2024					2,237	7 A		\$0 3		3,493		D	
Common Stock 05/15						5/2024					1,134	D	\$4	7.37	32,359			D	
Common Stock 05/1					5/2024				M		21,88	6 A	\perp	\$0 5		4,245		D	
Common Stock 05/					5/202	4			F ⁽²⁾ 9,074 D \$		\$4	7.37	7 45,171			D			
		٦	Table II -								osed of, onvertil				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	Date, Transac Code (I		of E		Expiratio	6. Date Exercis Expiration Date (Month/Day/Yea		7. Title and Ame of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amo or Num of Shar	oer					
Restricted Stock Unit ⁽³⁾	(4)	05/15/2024			M			792	(5)		(5)	Common Stock	79	2	\$0	3,170		D	

Explanation of Responses:

(4)

(9)

05/15/2024

05/15/2024

1. The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 16, 2023 through May 15, 2024. This transaction is also exempt under Rule 16b-3(c).

(7)

(10)

- 2. Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
- 3. Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).
- 4. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

2.237

21,886

- 5. RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.
- 6. Awarded on May 25, 2022 pursuant to the 2013 Plan.
- 7. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
- 8. Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan).
- 9. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
- 10. RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Remarks:

Restricted

Stock

Unit(6) Restricted

Stock

Unit⁽⁸⁾

/s/ Rachel Malina, Attorney-in-Fact for John F. Sheridan

05/17/2024

8,945

43,773

D

D

** Signature of Reporting Person

Common

Stock

Commor

Stock

(7)

(10)

2,237

21,886

\$0

\$0

Date

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

 ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.